The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such case, known as the 'Berlin Patient.'
Both patients were treated with stem cell transplants from donors carrying a genetic mutation that prevents expression of an HIV receptor CCR5.
The subject of the new study has been in remission for 18 months after his antiretroviral therapy (ARV) was discontinued. The authors say it is too early to say with certainty that he has been cured of HIV, and will continue to monitor his condition.
"At the moment the only way to treat HIV is with medications that suppress the virus, which people need to take for their entire lives, posing a particular challenge in developing countries," said the study's lead author, Professor Ravindra Gupta (UCL, UCLH and University of Cambridge).
"Finding a way to eliminate the virus entirely is an urgent global priority, but is particularly difficult because the virus integrates into the white blood cells of its host."
Close to 37 million people are living with HIV worldwide, but only 59% are receiving ARV, and drug-resistant HIV is a growing concern. Almost one million people die annually from HIV-related causes.*
The report describes a male patient in the UK, who prefers to remain anonymous, and was diagnosed with HIV infection in 2003 and on antiretroviral therapy since 2012.
Later in 2012, he was diagnosed with advanced Hodgkin’s Lymphoma. In addition to chemotherapy, he underwent a haematopoietic stem cell transplant from a donor with two copies of the CCR5 Δ32 allele in 2016.
CCR5 is the most commonly used receptor by HIV-1. People who have two mutated copies of the CCR5 allele are resistant to the HIV-1 virus strain that uses this receptor, as the virus cannot enter host cells.
Chemotherapy can be effective against HIV as it kills cells that are dividing. Replacing immune cells with those that don’t have the CCR5 receptor appears to be key in preventing HIV from rebounding after the treatment.
The transplant was relatively uncomplicated, but with some side effects including mild graft-versus-host disease, a complication of transplants wherein the donor immune cells attack the recipient’s immune cells.
The patient remained on ARV for 16 months after the transplant, at which point the clinical team and the patient decided to interrupt ARV therapy to test if the patient was truly in HIV-1 remission.
Regular testing confirmed that the patient's viral load remained undetectable, and he has been in remission for 18 months since ceasing ARV therapy (35 months post-transplant). The patient's immune cells remain unable to express the CCR5 receptor.
He is only the second person documented to be in sustained remission without ARV. The first, the Berlin Patient, also received a stem cell transplant from a donor with two CCR5 Δ32 alleles, but to treat leukaemia. Notable differences were that the Berlin Patient was given two transplants, and underwent total body irradiation, while the UK patient received just one transplant and less intensive chemotherapy.
Both patients experienced mild graft-versus-host disease, which may also have played a role in the loss of HIV-infected cells.
"By achieving remission in a second patient using a similar approach, we have shown that the Berlin Patient was not an anomaly, and that it really was the treatment approaches that eliminated HIV in these two people," said Professor Gupta.
The researchers caution that the approach is not appropriate as a standard HIV treatment due to the toxicity of chemotherapy, but it offers hope for new treatment strategies that might eliminate HIV altogether.
"Continuing our research, we need to understand if we could knock out this receptor in people with HIV, which may be possible with gene therapy," said Professor Gupta.
"The treatment we used was different from that used on the Berlin Patient, because it did not involve radiotherapy. Its effectiveness underlines the importance of developing new strategies based on preventing CCR5 expression," saidco-author Dr Ian Gabriel (Imperial College Healthcare NHS Trust).
"While it is too early to say with certainty that our patient is now cured of HIV, and doctors will continue to monitor his condition, the apparent success of haematopoietic stem cell transplantation offers hope in the search for a long-awaited cure for HIV/AIDS," said Professor Eduardo Olavarria (Imperial College Healthcare NHS Trust and Imperial College London).
The research was funded by Wellcome, the Medical Research Council, the Foundation for AIDS Research, and National Institute for Health Research (NIHR) Biomedical Research Centres at University College London Hospitals, Oxford, Cambridge and Imperial.
The research team is presenting the findings today (March 5) at the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Notes to Editors
For more information or to speak to the researchers involved, please contact Chris Lane, UCL Media Relations. T: +44 (0)20 7679 9222 / +44 (0)7717 728 648, E: email@example.com
Ravindra Gupta, Sultan Abduljawad, Laura McCoy , Hoi Ping Mok, Dimitra Peppa, Maria Salgado, Javier Martinez-Picado, Monique Nijhuis, Annemarie Wensing, Helen Lee, Paul Grant, Eleni Nastouli, Jonathan Lambert, Matthew Pace, Fanny Salasc, Christopher Monit, Andrew Innes, Luke Muir, Laura Waters, John Frater, Andrew Lever, Edwards SG, Ian Gabriel, and Eduardo Olavarria, ‘HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem cell transplantation' will be published in Nature on Tuesday 5 March 2019, 20:00 UK time / 12:00 US Pacific time and is under a strict embargo until this time.
The DOI for this paper will be10.1038/s41586-019-1027-4.
* Source: WHO
** HIV-1 is the most common and most harmful type of HIV. Of HIV-1, different strains use either the CCR5 or CXCR4 receptor of human immune cells, but most commonly CCR5.
About UCL (University College London)
UCL was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine.
We are among the world's top universities, as reflected by performance in a range of international rankings and tables, and are committed to changing the world for the better.
Our community of over 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.